Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-05-13

FDA Approved: PROCYSBI — Supplemental Application (Horizon Therapeutics USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for PROCYSBI (cysteamine bitartrate) from Horizon Therapeutics USA, Inc. The action constitutes an NDA supplement to the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Procysbi (mercaptamine bitartrate)

Snippet

SUPPL AP for PROCYSBI (CYSTEAMINE BITARTRATE)